ImmunityBio's Legal Deadline Looms Over Record Commercial Momentum

ImmunityBio reports record 168% revenue growth for its cancer drug ANKTIVA while investors face a May 26 deadline to join a securities lawsuit over an FDA warning letter.

ImmunityBio finds itself navigating a stark dichotomy as May approaches. The biotechnology firm is posting unprecedented sales for its cancer immunotherapy ANKTIVA while simultaneously preparing to defend against a consolidated securities class action lawsuit. Investors who purchased shares between January 19 and March 24, 2026, face a key deadline of May 26 to apply as lead plaintiff in the case.

The legal action stems from a regulatory misstep. On March 24, 2026, a warning letter from the U.S. Food and Drug Administration became public. Addressed to CEO Richard Adcock and dated March 13, the letter cited a TV advertisement and a company podcast for ANKTIVA as being "false or misleading," a violation of U.S. drug marketing laws. The stock reacted violently, shedding over 21% of its value in a single session and wiping out nearly $2 billion in market capitalization.

This sharp decline triggered a wave of legal activity. Law firms including Kessler Topaz Meltzer & Check, Robbins Geller, and Hagens Berman are now coordinating efforts in a single consolidated lawsuit, Douglas v. ImmunityBio, filed in a federal court in Central California. These firms allege securities fraud and are investigating potential violations of federal securities laws.

In response, ImmunityBio moved swiftly to address the FDA's concerns. By April 6, the company had submitted a comprehensive reply to the FDA's Office of Prescription Drug Promotion. It removed the cited podcast, clarified that the TV commercial had never actually aired, and announced enhanced internal review processes alongside external regulatory oversight.

This legal cloud stands in sharp contrast to the company's booming commercial performance. ImmunityBio reported preliminary net product revenue of approximately $44.2 million for the first quarter of 2026. This figure represents a staggering 168% increase year-over-year and a 15% sequential gain from the fourth quarter of 2025, marking the strongest quarter since ANKTIVA's launch. For the full year 2025, the company posted $113 million in revenue, a surge of roughly 700% compared to 2024.

Financially, the company appears well-buffered for a potential protracted legal battle. ImmunityBio ended the first quarter with a robust liquidity position of $380.9 million in cash, cash equivalents, and marketable securities, a significant increase from the $243 million reported at the end of Q4 2025.

Geographic expansion continues to build momentum for its flagship therapy. ANKTIVA recently gained approval in Macau for the treatment of BCG-unresponsive bladder cancer, marking its first regulatory clearance in Asia. The therapy is now approved across five regulatory jurisdictions encompassing 34 countries and territories. A separate approval in Saudi Arabia for non-small cell lung cancer was secured in January.

On the clinical front, development pipelines are advancing. The pivotal QUILT-2.005 trial in BCG-naive CIS, fully enrolled with 366 participants, has been confirmed by an independent data committee as adequately powered to meet its planned endpoint. The company plans to submit a supplemental Biologics License Application for this indication in 2026, including discussions with the FDA regarding an accelerated approval pathway.

The stock's recent trajectory reflects this dual narrative. Since the start of the year, shares have gained more than 260%, yet they have retreated approximately 13% over the past 30 days following the FDA letter. With the pending 10-Q filing and the structure of the class action lawsuit set to become clearer after the May 26 deadline, the coming weeks will test whether ImmunityBio's operational strength can outweigh its legal challenges.